Musa Hindiyeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Musa Hindiyeh has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Ella Mendelson
Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat-Gan, Israel; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
8 shared publicationsDaniela Ram
Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat-Gan, Israel
6 shared publicationsZehava Grossman
Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Israel
5 shared publicationsMichal Mandelboim
Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat-Gan, Israel; Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
4 shared publicationsNathan Keller
Sheba Medical Center
4 shared publicationsAfaf Abu-Diab
3 shared publications
Latest Publications
- 1 October 2018
- Published by Elsevier in Journal of Clinical Virology
- Vol. 107, 19-24
Characterization of human parainfluenza virus-3 circulating in Israel, 2012-2015
- 1 October 2018
- Published by Elsevier in Journal of Clinical Virology
- Vol. 107, 19-24
Characterization of human parainfluenza virus-3 circulating in Israel, 2012-2015
- Open Access
Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1
Human coronaviruses (HCoVs) cause mild to severe respiratory diseases. Six types of HCoVs have been discovered, the most recent one termed the Middle East respiratory syndrome coronavirus (MERS-CoV). The aim of this study is to monitor the circulation of HCoV types in the population during 2015–2016 in Israel. HCoVs were detected by real-time PCR analysis in 1910 respiratory samples, collected from influenza-like illness (ILI) patients during the winter sentinel influenza survey across Israel. Moreover, 195 HCoV-positive samples from hospitalized patients were detected during one year at Soroka University Medical Center. While no MERS-CoV infections were detected, 10.36% of patients in the survey were infected with HCoV-OC43 (43.43%), HCoV-NL63 (44.95%), and HCoV-229E (11.62%) viruses. The HCoVs were shown to co-circulate with respiratory syncytial virus (RSV) and to appear prior to influenza virus infections. HCoV clinical symptoms were more severe than those of RSV infections but milder than influenza symptoms. Hospitalized patients had similar HCoV types percentages. However, while it was absent from the public winter survey, 22.6% of the patients were HCoV-HKU1 positives, mainly during the spring-summer period.
Open AccessHuman Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1
Human coronaviruses (HCoVs) cause mild to severe respiratory diseases. Six types of HCoVs have been discovered, the most recent one termed the Middle East respiratory syndrome coronavirus (MERS-CoV). The aim of this study is to monitor the circulation of HCoV types in the population during 2015–2016 in Israel. HCoVs were detected by real-time PCR analysis in 1910 respiratory samples, collected from influenza-like illness (ILI) patients during the winter sentinel influenza survey across Israel. Moreover, 195 HCoV-positive samples from hospitalized patients were detected during one year at Soroka University Medical Center. While no MERS-CoV infections were detected, 10.36% of patients in the survey were infected with HCoV-OC43 (43.43%), HCoV-NL63 (44.95%), and HCoV-229E (11.62%) viruses. The HCoVs were shown to co-circulate with respiratory syncytial virus (RSV) and to appear prior to influenza virus infections. HCoV clinical symptoms were more severe than those of RSV infections but milder than influenza symptoms. Hospitalized patients had similar HCoV types percentages. However, while it was absent from the public winter survey, 22.6% of the patients were HCoV-HKU1 positives, mainly during the spring-summer period.
- 24 September 2014
- Published by Springer Nature
- Vol. 1237, 97-108
Molecular Detection of Antibiotic Resistance Genes from Positive Blood Cultures
Rapid detection of the bacterial causative agent causing sepsis must be coupled with rapid identification of the antibiotic resistant mechanism that the pathogen might possess. Real-time PCR (qPCR)-based assays have been extensively utilized in the clinical microbiology field as diagnostic tools for the rapid detection of specific nucleic acid (NA) targets. In this chapter, we will discuss the technical aspects of using an internally controlled qPCR assay for the rapid detection of Klebsiella pneumoniae carbapenemase gene (bla KPC) in positive Bactec blood culture bottles. The multiplex qPCR (bla KPC/RNase P) utilizes specific primers and probes for the detection of the bacterial carbapenem resistance mechanism, bla KPC gene, and the internal control RNase P. The internal control of the qPCR assay is vital for detecting any inhibitors that are well known to be present in the blood culture bottles. Rapid detection of the antibiotic resistant mechanism present in the bacterial pathogen causing sepsis can help in better managing patients’ infection.
- 24 September 2014
- Published by Springer Nature
- Vol. 1237, 97-108
Molecular Detection of Antibiotic Resistance Genes from Positive Blood Cultures
Rapid detection of the bacterial causative agent causing sepsis must be coupled with rapid identification of the antibiotic resistant mechanism that the pathogen might possess. Real-time PCR (qPCR)-based assays have been extensively utilized in the clinical microbiology field as diagnostic tools for the rapid detection of specific nucleic acid (NA) targets. In this chapter, we will discuss the technical aspects of using an internally controlled qPCR assay for the rapid detection of Klebsiella pneumoniae carbapenemase gene (bla KPC) in positive Bactec blood culture bottles. The multiplex qPCR (bla KPC/RNase P) utilizes specific primers and probes for the detection of the bacterial carbapenem resistance mechanism, bla KPC gene, and the internal control RNase P. The internal control of the qPCR assay is vital for detecting any inhibitors that are well known to be present in the blood culture bottles. Rapid detection of the antibiotic resistant mechanism present in the bacterial pathogen causing sepsis can help in better managing patients’ infection.
- Open Access
- 1 July 2013
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 51  (7) , 2421-2424
Evaluation of Simplexa Flu A/B & RSV for Direct Detection of Influenza Viruses (A and B) and Respiratory Syncytial Virus in Patient Clinical Samples
We evaluated the performance of the Simplexa Flu A/B & RSV kit on 170 prospective respiratory samples using a modified protocol, supplied by the manufacturer, that eliminates the RNA extraction step. Overall, compared against our laboratory-developed assay, the assay's sensitivity, specificity, and positive and negative predictive values were 95.1%, 99.6%, 98.7%, and 98.6%, respectively.
- 1 July 2013
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 51  (7) , 2421-2424
Open AccessEvaluation of Simplexa Flu A/B & RSV for Direct Detection of Influenza Viruses (A and B) and Respiratory Syncytial Virus in Patient Clinical Samples
We evaluated the performance of the Simplexa Flu A/B & RSV kit on 170 prospective respiratory samples using a modified protocol, supplied by the manufacturer, that eliminates the RNA extraction step. Overall, compared against our laboratory-developed assay, the assay's sensitivity, specificity, and positive and negative predictive values were 95.1%, 99.6%, 98.7%, and 98.6%, respectively.
- 1 July 2011
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 49  (7) , 2480-2484
Rapid Detection of bla KPC Carbapenemase Genes by Internally Controlled Real-Time PCR Assay Using Bactec Blood Culture Bottles
Rapid detection of drug-resistant bacteria in clinical samples plays an instrumental role in patients' infection management and in implementing effective infection control policies. In the study described in this report, we validated a multiplex TaqMan real-time quantitative PCR (qPCR) assay for the detection of bla KPC genes and the human RNase P gene in Bactec blood culture bottles. The MagNA Pure LC (version 2.0) instrument was utilized to extract nucleic acids from the inoculated broth, while bovine serum albumin (BSA) was utilized as the PCR inhibitor reliever. The multiplex assay, which was specific for the detection of bla KPC genes, had a limit of detection of 19 CFU per reaction mixture with human blood-spiked Bactec bottles. Of the 323 Bactec blood culture sets evaluated, the same 55 (17%) blood cultures positive for carbapenem-resistant bacteria by culture were also positive by the validated qPCR assay. Thus, the sensitivity, specificity, positive predictive value, and negative predictive value of the qPCR assay compared to the results of culture were all 100%. bla KPC genes were also detected from the same Bactec bottle broth after manual extraction with a QIAamp DNA minikit; however, there was an average 3-threshold-cycle delay in the qPCR readings. With the limited therapeutic options available, the accurate and rapid detection of bla KPC -possessing bacteria by the described bla KPC /RNase P assay will be a crucial first step in ensuring optimal clinical outcomes and infection control.
- 1 July 2011
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 49  (7) , 2480-2484
Rapid Detection of bla KPC Carbapenemase Genes by Internally Controlled Real-Time PCR Assay Using Bactec Blood Culture Bottles
Rapid detection of drug-resistant bacteria in clinical samples plays an instrumental role in patients' infection management and in implementing effective infection control policies. In the study described in this report, we validated a multiplex TaqMan real-time quantitative PCR (qPCR) assay for the detection of bla KPC genes and the human RNase P gene in Bactec blood culture bottles. The MagNA Pure LC (version 2.0) instrument was utilized to extract nucleic acids from the inoculated broth, while bovine serum albumin (BSA) was utilized as the PCR inhibitor reliever. The multiplex assay, which was specific for the detection of bla KPC genes, had a limit of detection of 19 CFU per reaction mixture with human blood-spiked Bactec bottles. Of the 323 Bactec blood culture sets evaluated, the same 55 (17%) blood cultures positive for carbapenem-resistant bacteria by culture were also positive by the validated qPCR assay. Thus, the sensitivity, specificity, positive predictive value, and negative predictive value of the qPCR assay compared to the results of culture were all 100%. bla KPC genes were also detected from the same Bactec bottle broth after manual extraction with a QIAamp DNA minikit; however, there was an average 3-threshold-cycle delay in the qPCR readings. With the limited therapeutic options available, the accurate and rapid detection of bla KPC -possessing bacteria by the described bla KPC /RNase P assay will be a crucial first step in ensuring optimal clinical outcomes and infection control.
- Open Access
- 1 January 2011
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 17  (1) , 94-96
Serotype Distribution and Drug Resistance inStreptococcus pneumoniae, Palestinian Territories
To determine antimicrobial drug resistance of Streptococcus pneumoniae serotypes, we analyzed isolates from blood cultures of sick children residing in the West Bank before initiation of pneumococcal vaccination. Of 120 serotypes isolated, 50.8%, 73.3%, and 80.8% of the bacteremia cases could have been prevented by pneumococcal conjugate vaccines. Serotype 14 was the most drug-resistant serotype isolated.
- 1 January 2011
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 17  (1) , 94-96
Open AccessSerotype Distribution and Drug Resistance inStreptococcus pneumoniae, Palestinian Territories
To determine antimicrobial drug resistance of Streptococcus pneumoniae serotypes, we analyzed isolates from blood cultures of sick children residing in the West Bank before initiation of pneumococcal vaccination. Of 120 serotypes isolated, 50.8%, 73.3%, and 80.8% of the bacteremia cases could have been prevented by pneumococcal conjugate vaccines. Serotype 14 was the most drug-resistant serotype isolated.
- 1 May 2010
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48  (5) , 1884-1887
Rapid Detection of Influenza A Pandemic (H1N1) 2009 Virus Neuraminidase Resistance Mutation H275Y by Real-Time Reverse Transcriptase PCR
The emergence of oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus highlights the need for rapid oseltamivir resistance screening. We report the development and validation of high-throughput real-time reverse transcriptase PCR assays for the detection of the H275Y substitution in the neuraminidase 1 gene that can be accomplished in 3 to 4 h.
- 1 May 2010
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48  (5) , 1884-1887
Rapid Detection of Influenza A Pandemic (H1N1) 2009 Virus Neuraminidase Resistance Mutation H275Y by Real-Time Reverse Transcriptase PCR
The emergence of oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus highlights the need for rapid oseltamivir resistance screening. We report the development and validation of high-throughput real-time reverse transcriptase PCR assays for the detection of the H275Y substitution in the neuraminidase 1 gene that can be accomplished in 3 to 4 h.
- 1 October 2009
- Vol. 148  (10) , 677-81, 735
[Laboratory diagnosis of influenza H1N1 2009 at the Central Virology Laboratory in Israel during the first 12 weeks of the pandemic].
Diagnosis of new emerging viruses in Israel is the responsibility of the Ministry of Health's Central Virology Laboratory (CVL). In April 2009, following the emergence of influenza H1N1 2009 virus in Mexico and the WHO declaration of pandemia, the Israeli preparedness plan was launched. Development and application of a diagnostic test for H1N1 2009, diagnosis of cases in an outbreak setting and data analysis. In the absence of a validated test to detect the new strain of H1N1 2009, an RT-PCR amplification of a highly conserved matrix (M) gene of influenza A virus was employed. All positive PCR products were sequenced and compared to sequences in the GenBank. At a later stage, a specific kit provided by the WHO was used. Further improvements were introduced including "in-house" developed assays. Arrangements were made to allow around-the-clock testing of hundreds of samples without compromising other laboratory services. Between April 27th and mid July, 2809 samples were tested of which 1082 (38.5%) were positive. Most of the cases were found in the central part of Israel and around Jerusalem. The highest morbidity was in the 20-29 years age group, with the highest rate of positive cases in the 10-19 years age group. More males than females were ill. When a large outbreak of a novel infectious agent occurs, a supreme quality laboratory is essential. The Israel CVL made possible an early and prompt identification of H1N1 2009 from the outset and has met its ongoing challenges with a high degree of success.
- 1 October 2009
- Vol. 148  (10) , 677-81, 735
[Laboratory diagnosis of influenza H1N1 2009 at the Central Virology Laboratory in Israel during the first 12 weeks of the pandemic].
Diagnosis of new emerging viruses in Israel is the responsibility of the Ministry of Health's Central Virology Laboratory (CVL). In April 2009, following the emergence of influenza H1N1 2009 virus in Mexico and the WHO declaration of pandemia, the Israeli preparedness plan was launched. Development and application of a diagnostic test for H1N1 2009, diagnosis of cases in an outbreak setting and data analysis. In the absence of a validated test to detect the new strain of H1N1 2009, an RT-PCR amplification of a highly conserved matrix (M) gene of influenza A virus was employed. All positive PCR products were sequenced and compared to sequences in the GenBank. At a later stage, a specific kit provided by the WHO was used. Further improvements were introduced including "in-house" developed assays. Arrangements were made to allow around-the-clock testing of hundreds of samples without compromising other laboratory services. Between April 27th and mid July, 2809 samples were tested of which 1082 (38.5%) were positive. Most of the cases were found in the central part of Israel and around Jerusalem. The highest morbidity was in the 20-29 years age group, with the highest rate of positive cases in the 10-19 years age group. More males than females were ill. When a large outbreak of a novel infectious agent occurs, a supreme quality laboratory is essential. The Israel CVL made possible an early and prompt identification of H1N1 2009 from the outset and has met its ongoing challenges with a high degree of success.
- 1 March 2009
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47  (3) , 560-565
Characterization of Large Mumps Outbreak among Vaccinated Palestinian Refugees
During a large mumps virus (MuV) outbreak which occurred in the Palestinian refugee camps of the West Bank, 68.1% (2,636/3,871) of the cases were vaccinated with one dose of trivalent measles, mumps, and rubella (MMR) vaccine. Attack rates by camp ranged from less than 1 case per 1,000 people in the population to 43/1,000 (overall, 11/1,000). The outbreak lasted from December 2003 to June 2005, with two peaks, one from April to May 2004 and the other from March to April 2005. To control the outbreak, a mass MMR vaccination campaign was conducted in May 2005. Evaluation of the immune status of cases ( n = 59) and healthy controls ( n = 51) revealed high levels of mumps immunoglobulin G (IgG) and a low MuV-specific IgM in clinical cases indicative of a booster immune response. This suggested a secondary rather than a primary infection due to the insufficient protection conferred by the single vaccine dose included in the vaccination program. This prediction was further confirmed by the low seroprevalence (68.6%) found in the healthy control group, which was below the threshold level required for MuV herd immunity. Mumps diagnosis was established mainly by reverse transcription-PCR in clinical samples obtained within 48 h from the onset of disease. Of the parotid fluids and nasopharyngeal aspirates analyzed, 92% were positive for MuV RNA, while only 33% of the urine samples were positive. Phylogenetic analysis of the MuV SH gene identified the outbreak strain as the H genotype, which has been in circulation worldwide at least since 1989.
- 1 March 2009
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47  (3) , 560-565
Characterization of Large Mumps Outbreak among Vaccinated Palestinian Refugees
During a large mumps virus (MuV) outbreak which occurred in the Palestinian refugee camps of the West Bank, 68.1% (2,636/3,871) of the cases were vaccinated with one dose of trivalent measles, mumps, and rubella (MMR) vaccine. Attack rates by camp ranged from less than 1 case per 1,000 people in the population to 43/1,000 (overall, 11/1,000). The outbreak lasted from December 2003 to June 2005, with two peaks, one from April to May 2004 and the other from March to April 2005. To control the outbreak, a mass MMR vaccination campaign was conducted in May 2005. Evaluation of the immune status of cases ( n = 59) and healthy controls ( n = 51) revealed high levels of mumps immunoglobulin G (IgG) and a low MuV-specific IgM in clinical cases indicative of a booster immune response. This suggested a secondary rather than a primary infection due to the insufficient protection conferred by the single vaccine dose included in the vaccination program. This prediction was further confirmed by the low seroprevalence (68.6%) found in the healthy control group, which was below the threshold level required for MuV herd immunity. Mumps diagnosis was established mainly by reverse transcription-PCR in clinical samples obtained within 48 h from the onset of disease. Of the parotid fluids and nasopharyngeal aspirates analyzed, 92% were positive for MuV RNA, while only 33% of the urine samples were positive. Phylogenetic analysis of the MuV SH gene identified the outbreak strain as the H genotype, which has been in circulation worldwide at least since 1989.